No CrossRef data available.
Article contents
The Expanding Role of Antipsychotics
Published online by Cambridge University Press: 07 November 2014
Extract
Antipsychotics have been utilized in the treatment of bipolar disorder for many decades and were the mainstay of treatment before lithium was reintroduced in the late 1960s. Today, many bipolar patients who present with psychotic features are misdiagnosed and prescribed an antipsychotic for another disorder. Estimates of psychotic symptoms in bipolar disorder, particularly during a manic episode, are ≥50% by clinical assessment and even higher by individual reports. Thus, antipsychotics are frequently used: as first treatment for psychosis not recognized as bipolar disorder, and as an adjunct to a mood-stabilizing agent in bipolars with psychotic symptoms.
Most recently, antipsychotics have been examined for their mood-stabilizing properties as well (Slide 9). One may conceptualize using a selective serotonin reuptake inhibitor (SSRI) antidepressant for disorders such as panic disorder or obsessive-compulsive disorder, and using an antiepileptic as a mood-stabilizing agent; however, it is more difficult to accept that an agent approved for treatment of psychosis can be a primary therapy for bipolar disorder. Data from the monotherapy trials suggest that second-generation antipsychotics (SGAs) are at least as effective as lithium and valproic acid for acute mania. There is a very large database indicating that SGAs can be utilized as monotherapy for acute mania. However, there is limited data on the role of these agents in prevention of relapse and recurrence and in their efficacy for depression in the context of bipolar disorder. More studies will be needed to clarify whether SGAs should be used as monotherapy or whether they would be best used as augmenting agents in severe and psychotically manic or depressed patients.
- Type
- Research Article
- Information
- Copyright
- Copyright © Cambridge University Press 2004
References
1.Shi, L, Namjoshi, MA, Zhang, F, et al.Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol. 2002;17:227–237.CrossRefGoogle ScholarPubMed
2.Tohen, M, Sanger, TM, McElroy, SL, et al.Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156:702–709.CrossRefGoogle ScholarPubMed
3.Goodwin, FK, Fireman, B, Simon, GE, et al.Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467–1473.CrossRefGoogle ScholarPubMed
4.Tohen, M, Jacobs, TG, Grundy, SL, et al.Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;9:841–849.CrossRefGoogle Scholar
5.Meehan, K, Zhang, F, David, S, et al.A double-blind, randomized comparison of the efficacy and safety of intramuscular (IM) olanzapine versus IM lorazepam and IM placebo in acutely agitated patients diagnosed with mania associated with bipolar disorder. J Clin Psychopharmacol. 2001;21:389–397.CrossRefGoogle Scholar
6.Hirschfeld, R, Keck, PE, Karcher, K, et al.Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Presented at: 41st Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 2001; San Juan, Puerto Rico.Google Scholar
7.Vieta, E, Khauna, S, Lyons, B, et al.Risperidone in the treatment of manic or mixed episodes of bipolar disorder. Presented at: 41st Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 2001; San Juan, Puerto Rico.Google Scholar
8.Keck, PE, Versiani, M, Potkin, S, et al.Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.Am J Psychiatry. 2003;160:741–748.CrossRefGoogle Scholar
9.Brooks, S, Lucey, JV, Gunn, KP, et al.Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933–941.CrossRefGoogle Scholar
10.Keck, PE, Marcus, R, Tourkodimitris, S, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. In press.Google Scholar
11.Brecher, M, Hulzar, K. Quetiapine versus placebo for acute mania associated with bipolar disorder (STAMP 1). Presented at: Annual Meeting of the International Society for Bipolar Disorders; June 12-14, 2003; Pittsburgh, PA.Google Scholar
12.Jones, M, Hulzer, K. Quetiapine monotherapy for mania associated with bipolar disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.Google Scholar
13.Sachs, GS, Grossman, P, Ghaemi, SN, et al.Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146–1154.CrossRefGoogle ScholarPubMed
14.Sachs, G, Mullen, JA, Devine, NA. Quetiapine vs placebo as adjunct to mood stabilizer for the treatment of acute mania. Poster presented at: 3rd European Stanley Foundation Conference on Bipolar Disorder; September 12-14, 2002; Freiburg, Germany.CrossRefGoogle Scholar
15.Tohen, M, Chengappa, NR, Suppes, T, et al.Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62–69.CrossRefGoogle ScholarPubMed
16.Bowden, CL, Calabrese, JR, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;4:392–400.CrossRefGoogle Scholar
17.Calabrese, JR, Bowden, CL, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;9:1013–1024.CrossRefGoogle Scholar